Company intelligence / Profile preview

Iterum Therapeutics plc

Ownership: Public · ITRM
Development stage: Phase 3

Overview

Iterum Therapeutics has received FDA approval for ORLYNVAH™ (oral sulopenem), the first and only approved oral penem antibiotic in the U.S., indicated for uncomplicated urinary tract infections caused by certain multi-drug resistant pathogens. The company’s lead asset addresses a significant unmet need as it targets patients with limited or no alternative oral antibiotic treatments. Sulopenem has demonstrated potent activity against a broad spectrum of drug-resistant bacteria. Pre-commercialization activities are underway to launch ORLYNVAH™ in the U.S.

Therapeutic areas: Infectious Diseases
Modalities: small molecules (specifically penem-class antibiotics)
Industry: Biotech

Drug pipeline

3 assets

sulopenem

2 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed; outreach to strategic partners ongoing as of early 2025.H.C. Wainwright & Co served as placement agent for recent financing rounds.

Financials

Market cap: $1.6M
Total revenue: $390K
Enterprise value: $24.3M

Beyond the preview

Go deeper on Iterum Therapeutics plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iterum Therapeutics plc.

Explore the full profile